Travere Therapeutics, Inc.(TVTX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Travere Therapeutics, Inc. (TVTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVTX at 56.6/100 on a 32-signal composite quality model, placing it at rank #1,149 of 2,962 stocks — the top half of the AI-ranked universe. TVTX scores in the top quartile across revenue growth (96.1), earnings quality (84.9). Areas of concern include balance sheet strength (20.6) and profitability (29.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Travere Therapeutics, Inc. reports quarterly revenue of $169.6M, net income of $-34.8M. Top institutional holders of TVTX by reported 13-F value include Jupiter Topco, BlackRock, FMR, based on the most recent SEC filings. TVTX trades on the Nasdaq exchange and files with the SEC under CIK 1438533. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Travere Therapeutics, Inc. directly from SEC EDGAR.